Vascular disease
Conditions
Interventions
Ulastatin group :Dissolve 5000U/kg of Ulastatin in 100ml of physiological saline and administer it intravenously.Timing of administration: After the surgeon completes the puncture, the infusion is com
Control group :Administer 100ml of physiological saline solution
Timing of administration: After the surgeon completes the puncture, the infusion is completed before stent placement
Sponsors
Third Affiliated Hospital of Sun Yat sen University, Guangzhou, Guangdong Province
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Voluntarily signed informed consent 2. Age> 18 years old, < 80 years old 3. Patients undergoing elective surgery under general anesthesia who have undergone cerebrovascular intervention 4. No signs of infection before surgery (normal body temperature before operation< 37.3°C; Chest x-ray does not suggest inflammation; White blood cell count (4.0~10.0)×10^9)
Exclusion criteria
Exclusion criteria: a. Emergency surgery, or secondary surgery after admission; b. Preoperative presence of SIRS; c. Suffering from autoimmune diseases, tumors, or receiving high-dose hormones and immunosuppressants within 2 months; d. Congestive heart failure, non-infectious cardiogenic shock, or uncontrolled acute blood loss of New York Heart Association grade 4; e.ASA > Class III f. Previous history of allergy to ulinastatin or any ingredient or preservative; g. Judged by the investigator to be unsuitable to participate in this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Changes in systemic immune inflammatory index (SII) during perioperative period; | — |
Secondary
| Measure | Time frame |
|---|---|
| IL-6;CRP;PQSI;MMSE;VAS;PONV;Incidence rate of SIRS within 3 days post-surgery; | — |
Countries
China
Contacts
Public ContactYao Weifeng
Third Affiliated Hospital of Sun Yat sen University, Guangzhou, Guangdong Province
Outcome results
None listed